# **GŁÓWNY INSPEKTORAT FARMACEUTYCZNY**

2021 -03- 1 0





### CHIEF PHARMACEUTICAL INSPECTOR

IWSF.405.4.2021.IP.1 WTC/0196\_02\_05/52

## CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER

#### Part 1

Issued following an inspection in accordance with Art. 111(5) of Directive 2001/83/EC as amended

## **Chief Pharmaceutical Inspector**

/the Competent Authority of Poland/

confirms the following:

the manufacturer

# Tarchomińskie Zakłady Farmaceutyczne "Polfa" Spółka Akcyjna ul. A. Fleminga 2, 03-176 Warszawa, POLAND

site address

# Tarchomińskie Zakłady Farmaceutyczne "Polfa" Spółka Akcyjna ul. A. Fleminga 2, 03-176 Warszawa, POLAND


has been inspected under the national inspection programme in connection with manufacturing authorisation No. 078/0196/15 in accordance with Art. 40 of Directive 2001/83/EC transposed in Pharmaceutical Law of 6th of September 2001 (Journal of Laws from 2020, item 944).

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on **07-11/12/2020**, it is considered that it complies with the Good Manufacturing Practice requirements laid down in Directive 2003/94/EC.

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field.

This certificate is valid only when presented with all pages and both Parts 1 and 2.

The authenticity of this certificate may be verified in EudraGMP. If it does not appear, please contact the issuing authority.





# GŁÓWNY INSPEKTORAT FARMACEUTYCZNY

#### Part 2

**Human Medicinal Products** 

1 MANUFACTURING OPERATIONS	
1.1	Sterile Products
	1.1.1 Aseptically prepared
	1.1.1.5 Solids and implants
	1.1.3 Batch certification
1.5	Packaging
	1.5.2 Secondary packing

### Any restrictions or clarifying remarks related to the scope of this certificate:

Point 1.1.1.5 concerns also manufacturing of medicinal products containing active substances from  $\beta$ -Lactam antibiotics group

Any restrictions or clarifying remarks related to the scope of this certificate:

The certificate was issued on the basis of remote inspection.

Chief Pharmaceutical Inspector

Ewa Krajewska